Trial Profile

A Phase 1/2a, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of PEN-866 in Patients With Advanced Solid Malignancies

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 07 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Locnartecan (Primary) ; Fluorouracil; Folinic acid
Indications Adenocarcinoma; Anal cancer; Cervical cancer; Colon cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; Liposarcoma; Oesophageal cancer; Pancreatic cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Tarveda Therapeutics

16 Feb 2022 Planned End Date changed from 1 Jun 2022 to 1 Jun 2023.
16 Feb 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Jan 2023.
08 Mar 2021 Planned number of patients changed from 290 to 340.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com